Patients with Brugada syndrome who have survived an aborted cardiac arrest, or who have documented spontaneous sustained ventricular tachycardia, form a distinct high-risk group requiring a specific, structured clinical approach.
This protocol applies to Brugada syndrome in two well-defined situations: survival of an aborted cardiac arrest and/or the presence of documented spontaneous sustained ventricular tachycardia. Guidelines identify device-based therapy as a central recommendation in this population.
An antiarrhythmic agent is part of the management strategy considered in this setting — particularly in specific clinical circumstances where device-based therapy is not the chosen route.
DOI: 10.1093/eurheartj/ehac262
ICD implantation is recommended in patients with BrS who: (a) Are survivors of an aborted CA and/or (b) Have documented spontaneous sustained VT.
Quinidine should be considered in patients with BrS who qualify for an ICD but have a contraindication, decline, or have recurrent ICD shocks.
View source ↗